Mosapride combined with rebamipide demonstrates superior efficacy for treatment of chronic atrophic gastritis
The combination of mosapride and rebamipide offers superior efficacy in managing CAG without increasing adverse effects. It significantly improves pathological conditions, expedites symptom resolution, and enhances gastric mucosal biomarker profiles, supporting its broader clinical application.
Authors
- Sisi Shen
Institutions
- Huzhou Normal University (CN)
- Third People's Hospital of Huzhou (CN)
- Huzhou Women and Children's Hospital (CN)
Publication Details
- Journal
- American Journal of Translational Research
- Published
- 2025-01-01
- DOI
- https://doi.org/10.62347/ymob9811
- Citations
- 1
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01